search
Back to results

Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma (S-1226(8%))

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
S1226(8%)
Placebo
Sponsored by
SolAeroMed Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring COPD, Chronic bronchitis, Cystic fibrosis, Bronchoconstriction, Perfluorocarbons, Carbon dioxide

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female subjects 18-40 years of age.
  2. BMI of 18-40 kg/m2
  3. Subject is not currently on topical or systemic corticosteroids and has not taken any oral/injectable corticosteroid within 60 days prior to study drug administration and has not used any inhaled/nasal corticosteroid within 30 days prior to study drug administration.
  4. Female subjects must not be pregnant or lactating and must be practicing an acceptable method of birth control, or be surgically sterile or postmenopausal.
  5. Subjects must have had asthma for at least 3 months.
  6. Subject is a non-smoker or has not smoked for > 1year and has < 10 pack-year history.
  7. Subject has a methacholine PC20 of less than 16mg/mL.
  8. Subject has normal laboratory values (normal values as clinically judged by the Investigator) for clinical chemistry, hematology, and urinalysis.
  9. Subject is in general good health based on medical history and clinically acceptable results for the following assessments: physical examination, vital signs, and 12-lead ECG, as assessed by study physicians.
  10. Subject is able to communicate effectively with study personnel and is reliable, willing and cooperative in terms of compliance with protocol.

Exclusion Criteria:

Subjects to whom any of the following applies will be excluded from the study:

  1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
  2. Subjects who require inhaled β2-agonist medication more frequently than 4 times a week (other than prophylactically prior to exercise) during the 4 week period before screening.
  3. Subjects who are currently treated with any asthma medication other than inhaled β2-agonist.
  4. Subjects with frequent emergency room visits for asthma, with prior ICU admission or those with prior intubation.
  5. Presence or history of neurologic, endocrine, hepatic, gastrointestinal or kidney disease or therapy that would jeopardize the subject's well-being by participating in the study.
  6. Cardiovascular disease that, in the opinion of the Investigator, is not stable or could put the subject at increased risk by participating in the study.
  7. Any reason which, in the opinion of the Investigator (or delegate), would prevent the subject from participating in the study.
  8. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  9. Subject has a history of physician diagnosed panic disorder or other anxiety disorders.
  10. Subject is currently receiving treatment, or has received treatment in the previous 14 days, with monoamine oxidase (MAO) inhibitors.
  11. Subjects dosed with an investigational drug within 30 days prior to the Screening Visit.
  12. Subjects dosed with biologic therapy within the previous 4 months or 5 half-lives from baseline methacholine testing.
  13. Subject has current (or within the last six months) evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit)
  14. Positive urine drug screen or urine cotinine test at screening.
  15. Breast-feeding subject.
  16. Positive pregnancy test at screening.
  17. Subject, who in the opinion of the Investigator, is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.

Sites / Locations

  • Respiratory Clinical Trials Centre, University of Calgary

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

S1226 (8%)

Placebo

Arm Description

The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.

The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.

Outcomes

Primary Outcome Measures

The number of treatment emergent adverse events (AEs).
Subjects will be closely monitored throughout the 2-minute drug and placebo administration periods and for 120 minutes following treatment. Treatment may be stopped at any time at the request of the subject and/or the qualified investigator or delegate. Safety and tolerability to S-1226 (8%) will be evaluated through the assessment of adverse events, vital signs, pulse oximetry, biochemistry and hematology testing, urinalysis, 12-lead ECG, physical examination, and pulmonary function (spirometry). These data will be recorded and descriptive statistics and change from baseline for safety parameters will be reported.

Secondary Outcome Measures

Evaluate the efficacy of S-1226 (8%) in comparison to placebo. (evaluated using area under the curve (AUC) of the early asthmatic response (defined as a 20% fall from baseline FEV1 following allergen inhalation)
Efficacy will be evaluated using area under the curve (AUC) of the early asthmatic response (defined as a 20% fall from baseline FEV1 following allergen inhalation), responder status which is achieving ≥ 25% reversal over placebo of the decrease in FEV1 from allergen challenge within 30 minutes after study treatment, maximum percent reversal of allergen-induced decrease in FEV1 in the first 30 minutes following study treatment administration, and the duration of the ≥ 25% reversal produced by study drug, defined as the interval after S-1226 (8%) administration during which the FEV1 is maintained at ≥ 25% above placebo.

Full Information

First Posted
November 12, 2014
Last Updated
February 15, 2019
Sponsor
SolAeroMed Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02334553
Brief Title
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Acronym
S-1226(8%)
Official Title
Phase IIa, Placebo-controlled, Randomized, Double-blind, Crossover Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 (8%) Administered by Nebulization in Subjects With Mild Atopic Asthma.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
February 6, 2015 (Actual)
Primary Completion Date
November 25, 2015 (Actual)
Study Completion Date
November 25, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SolAeroMed Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.
Detailed Description
Phase IIa, placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%) administered by nebulization in subjects with mild atopic asthma

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
COPD, Chronic bronchitis, Cystic fibrosis, Bronchoconstriction, Perfluorocarbons, Carbon dioxide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
S1226 (8%)
Arm Type
Active Comparator
Arm Description
The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
Intervention Type
Drug
Intervention Name(s)
S1226(8%)
Other Intervention Name(s)
PFOB nebulized with 8% CO2 in medical gas mixture
Intervention Description
The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
normal saline nebulized with compressed medical air
Intervention Description
Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
Primary Outcome Measure Information:
Title
The number of treatment emergent adverse events (AEs).
Description
Subjects will be closely monitored throughout the 2-minute drug and placebo administration periods and for 120 minutes following treatment. Treatment may be stopped at any time at the request of the subject and/or the qualified investigator or delegate. Safety and tolerability to S-1226 (8%) will be evaluated through the assessment of adverse events, vital signs, pulse oximetry, biochemistry and hematology testing, urinalysis, 12-lead ECG, physical examination, and pulmonary function (spirometry). These data will be recorded and descriptive statistics and change from baseline for safety parameters will be reported.
Time Frame
120 minutes
Secondary Outcome Measure Information:
Title
Evaluate the efficacy of S-1226 (8%) in comparison to placebo. (evaluated using area under the curve (AUC) of the early asthmatic response (defined as a 20% fall from baseline FEV1 following allergen inhalation)
Description
Efficacy will be evaluated using area under the curve (AUC) of the early asthmatic response (defined as a 20% fall from baseline FEV1 following allergen inhalation), responder status which is achieving ≥ 25% reversal over placebo of the decrease in FEV1 from allergen challenge within 30 minutes after study treatment, maximum percent reversal of allergen-induced decrease in FEV1 in the first 30 minutes following study treatment administration, and the duration of the ≥ 25% reversal produced by study drug, defined as the interval after S-1226 (8%) administration during which the FEV1 is maintained at ≥ 25% above placebo.
Time Frame
30minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects 18-40 years of age. BMI of 18-40 kg/m2 Subject is not currently on topical or systemic corticosteroids and has not taken any oral/injectable corticosteroid within 60 days prior to study drug administration and has not used any inhaled/nasal corticosteroid within 30 days prior to study drug administration. Female subjects must not be pregnant or lactating and must be practicing an acceptable method of birth control, or be surgically sterile or postmenopausal. Subjects must have had asthma for at least 3 months. Subject is a non-smoker or has not smoked for > 1year and has < 10 pack-year history. Subject has a methacholine PC20 of less than 16mg/mL. Subject has normal laboratory values (normal values as clinically judged by the Investigator) for clinical chemistry, hematology, and urinalysis. Subject is in general good health based on medical history and clinically acceptable results for the following assessments: physical examination, vital signs, and 12-lead ECG, as assessed by study physicians. Subject is able to communicate effectively with study personnel and is reliable, willing and cooperative in terms of compliance with protocol. Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study: Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening. Subjects who require inhaled β2-agonist medication more frequently than 4 times a week (other than prophylactically prior to exercise) during the 4 week period before screening. Subjects who are currently treated with any asthma medication other than inhaled β2-agonist. Subjects with frequent emergency room visits for asthma, with prior ICU admission or those with prior intubation. Presence or history of neurologic, endocrine, hepatic, gastrointestinal or kidney disease or therapy that would jeopardize the subject's well-being by participating in the study. Cardiovascular disease that, in the opinion of the Investigator, is not stable or could put the subject at increased risk by participating in the study. Any reason which, in the opinion of the Investigator (or delegate), would prevent the subject from participating in the study. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening. Subject has a history of physician diagnosed panic disorder or other anxiety disorders. Subject is currently receiving treatment, or has received treatment in the previous 14 days, with monoamine oxidase (MAO) inhibitors. Subjects dosed with an investigational drug within 30 days prior to the Screening Visit. Subjects dosed with biologic therapy within the previous 4 months or 5 half-lives from baseline methacholine testing. Subject has current (or within the last six months) evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit) Positive urine drug screen or urine cotinine test at screening. Breast-feeding subject. Positive pregnancy test at screening. Subject, who in the opinion of the Investigator, is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Leigh, MD, PhD
Organizational Affiliation
Professor and Head, Respiratory Clinical Trials Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Veronica Swystun, PhD
Organizational Affiliation
Respiratory Clinical Trials Centre, University of Calgary
Official's Role
Study Director
Facility Information:
Facility Name
Respiratory Clinical Trials Centre, University of Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4Z6
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
25355286
Citation
El Mays TY, Choudhury P, Leigh R, Koumoundouros E, Van der Velden J, Shrestha G, Pieron CA, Dennis JH, Green FH, Snibson KJ. Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma. Respir Res. 2014 Sep 16;15(1):98. doi: 10.1186/s12931-014-0098-x.
Results Reference
background
PubMed Identifier
29914544
Citation
Swystun V, Green FHY, Dennis JH, Rampakakis E, Lalli G, Fadayomi M, Chiu A, Shrestha G, El Shahat SG, Nelson DE, El Mays TY, Pieron CA, Leigh R. A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma. Trials. 2018 Jun 18;19(1):321. doi: 10.1186/s13063-018-2720-6.
Results Reference
derived
Links:
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172894/
Description
Pre clinical sheep model for S-1226
URL
http://www.solaeromed.com
Description
Sponsoring company website

Learn more about this trial

Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma

We'll reach out to this number within 24 hrs